Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics (LUCD)
NASDAQ:LUCD
Total Valuation
Lucid Diagnostics has a market cap or net worth of $129.62M. The enterprise value is $101.11M.
Market Cap$129.62M
Enterprise Value$101.11M
Share Statistics
Lucid Diagnostics has 105,382,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding105,382,960
Owned by Insiders4.34%
Owned by Institutions1.66%
Financial Efficiency
Lucid Diagnostics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -666.61%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-666.61%
Return on Capital Employed (ROCE)-6.40
Revenue Per Employee60.36M
Profits Per Employee-632.35M
Employee Count72
Asset Turnover0.14
Inventory Turnover20.82K
Valuation Ratios
The current PE Ratio of Lucid Diagnostics is -0.91. Lucid Diagnostics’s PEG ratio is 0.02.
PE Ratio-0.91
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio0.02
Income Statement
In the last 12 months, Lucid Diagnostics had revenue of 4.35B and earned -45.53M in profits. Earnings per share was -0.75.
Revenue4.35B
Gross Profit-2.75B
Operating Income-46.05B
Pretax Income-45.53B
Net Income-45.53M
EBITDA-46.05B
Earnings Per Share (EPS)-0.75
Cash Flow
In the last 12 months, operating cash flow was -44.14M and capital expenditures -646.00K, giving a free cash flow of -44.79M billion.
Operating Cash Flow-44.14M
Free Cash Flow-44.79M
Free Cash Flow per Share-0.42
Dividends & Yields
Lucid Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.34
52-Week Price Change27.96%
50-Day Moving Average1.37
200-Day Moving Average1.02
Relative Strength Index (RSI)40.91
Average Volume (3m)1.28M
Important Dates
Lucid Diagnostics upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateMar 24, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
Lucid Diagnostics as a current ratio of 1.07, with Debt / Equity ratio of 394.25%
Current Ratio1.07
Quick Ratio1.07
Debt to Market Cap513.91
Net Debt to EBITDA0.02
Interest Coverage Ratio-1.77M
Taxes
In the past 12 months, Lucid Diagnostics has paid 7.50B in taxes.
Income Tax7.50B
Effective Tax Rate-0.16
Enterprise Valuation
Lucid Diagnostics EV to EBITDA ratio is 0.02, with an EV/FCF ratio of 0.02.
EV to Sales-0.24
EV to EBITDA0.02
EV to Free Cash Flow0.02
EV to Operating Cash Flow0.02
Balance Sheet
Lucid Diagnostics has $22.36M in cash and marketable securities with ― in debt, giving a net cash position of -$1.10M billion.
Cash & Marketable Securities$22.36M
Total Debt―
Net Cash-$1.10M
Net Cash Per Share-$0.01
Tangible Book Value Per Share$92.15
Margins
Gross margin is -80.14%, with operating margin of -1059.64%, and net profit margin of -1.05%.
Gross Margin-80.14%
Operating Margin-1059.64%
Pretax Margin-1047.61%
Net Profit Margin-1.05%
EBITDA Margin-1059.64%
EBIT Margin-1048.21%
Analyst Forecast
The average price target for Lucid Diagnostics is $3.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$3.75
Price Target Upside215.13% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast79.00%
EPS Growth Forecast15.03%